This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

23 May 2012

Lundbeck & CHDI Foundation Announce Research Collaboration

The collaboration aims to investigate a targeted therapy for Huntington’s disease.

CHDI Foundation, Inc. and Lundbeck have announced a research collaboration to investigate a targeted therapy for Huntington’s disease (HD).


Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.


As part of the collaboration CHDI will conduct pre-clinical studies on a Lundbeck investigative compound. Research will focus on the compound’s effect on P2X receptors that may be involved in HD. The study results will influence future research into this and other compounds for HD.


This collaboration is part of Lundbeck’s continued commitment to its

Related News